

Drug Utilization Review (DUR) Meeting Minutes September 17, 2012

Members Present: Norman Byers, John Savageau, Russ Sobotta, Todd Twogood, Tanya Schmidt, Leann Ness, David Clinkenbeard, Jeffrey Hostetter

Members Absent: Kim Krohn, James Carlson, Cheryl Huber, Greg Pfister, Carlotta McCleary, Steve Irsfeld, Carrie Sorenson

Medicaid Pharmacy Department: Brendan Joyce

HID Staff Present: Candace Rieth

D. Clinkenbeard called the meeting to order at 1:00 pm. D. Clinkenbeard asked for a motion to approve the minutes from the June meeting. T. Schmidt moved that the minutes be approved and L. Ness seconded the motion. D. Clinkenbeard called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce informed the board members that for the current fiscal year (7/11 – 6/12) the total pharmacy expenditure, net of rebate, was 17.5 million dollars. The actual payment to pharmacies (pre-rebate dollars) during that time was 37.1 million dollars. The unit rebate offset amount that is paid to the federal government was 1.5 million dollars. The class with the highest drug spend is ADHD. In August 2012, the spend for ADHD was approximately \$480,000.

Kalydeco Second Review

A motion and second were made at the June meeting to place Kalydeco on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, D. Clinkenbeard called for a voice vote to approve the motion. The motion passed with no audible dissent.

Kuvan Second Review

A motion and second were made at the June meeting to place Kuvan on prior authorization. The topic was brought up for a second review. There was no public comment. D. Clinkenbeard called for a voice vote to approve the motion. The motion passed with no audible dissent.

Elaprase Second Review

A motion and second were made at the June meeting to place Elaprase on prior authorization. The topic was brought up for a second review. There was no public comment. D. Clinkenbeard called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. DAW, Amrix/Fexmid, Xenical, Zanaflex caps, Ketek, Aczone, Topical Ketoconazole, Clorpres, Gilenya, Livalo, Oravig, Xyrem, Zyclara, Nuedexta, Nexiclon, and Narcotic/APAP combo products were reviewed. No changes were made to the forms and criteria.

Actinic Keratosis Review

B. Joyce reviewed actinic keratosis with the Board. There was no public comment. After discussion, T. Twogood made a motion to place products used to treat actinic keratosis on prior authorization. J. Hostetter seconded the motion. This topic will be brought up at the next meeting for finalization.

Moxeza Review

B. Joyce reviewed Moxeza information with the Board. Rachelle Dorr, representing Alcon, spoke against prior authorization of Moxeza. After discussion, N. Byers made a motion to place Moxeza on prior authorization. L. Ness seconded the motion. This topic will be brought up at the next meeting for finalization.

Lidoderm Review

B. Joyce reviewed Lidoderm information with the Board. There was no public comment. This topic was tabled.

Suboxone Review

B. Joyce reviewed Suboxone information with the Board. Jim Sharp, representing Reckitt Benckiser, spoke regarding Suboxone. This topic was tabled.

Patients Taking Multiple Long-Acting Narcotics and Oxycontin TID Review

B. Joyce reviewed patients taking multiple long-acting narcotics and Oxycontin three times a day with the Board. There was no public comment. After discussion, it was suggested that this topic be reviewed at the next meeting.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. J. Hostetter moved to approve the new criteria and N. Byers seconded the motion. D. Clinkenbeard called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held Dec 3rd, 2012 in Bismarck. D. Clinkenbeard made a motion to adjourn the meeting. N. Byers seconded. The motion passed with no audible dissent. D. Clinkenbeard adjourned the meeting at 2:47 pm.